Y0001062

Losartan Potassium

European Pharmacopoeia (EP) Reference Standard

• Sinónimos: 2-Butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)(1,1′-biphenyl)-4-yl]methyl}-1H-imidazole-5-methanol monopotassium salt
• Fórmula empírica (notación de Hill): C₂₂H₂₂ClKN₆O
• Número de CAS: 124750-99-8
• Peso molecular: 461.00
• Beilstein/REAXYS Number: 5845770
• MDL number: MFCD02092704
• UNSPSC Code: 41116107
• PubChem Substance ID: 329831243
• NACRES: NA.24

Propiedades

• grade: pharmaceutical primary standard
• API family: losartan
• manufacturer/tradename: EDQM
• application(s): pharmaceutical (small molecule)
• format: neat
• SMILES string: CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)-c3ccccc3-c4nnnn4[K]
• InChI: 1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
• InChI key: OXCMYAYHXIHQOA-UHFFFAOYSA-N
• Gene Information: human ... AGTR1(185)

Descripción

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Losartan potassium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Losartan potassium is an orally available, potent, and selective competitive angiotensin II receptor type 1 (AT1) antagonist. Losartan potassium is used for treatment of hypertension.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable